CA3144755A1 - Method of inhibiting or activating gamma delta t cells - Google Patents

Method of inhibiting or activating gamma delta t cells Download PDF

Info

Publication number
CA3144755A1
CA3144755A1 CA3144755A CA3144755A CA3144755A1 CA 3144755 A1 CA3144755 A1 CA 3144755A1 CA 3144755 A CA3144755 A CA 3144755A CA 3144755 A CA3144755 A CA 3144755A CA 3144755 A1 CA3144755 A1 CA 3144755A1
Authority
CA
Canada
Prior art keywords
btn2a1
cells
seq
btn3a1
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3144755A
Other languages
English (en)
French (fr)
Inventor
Andreas BEHREN
Jonathan Cebon
Marc Rigau CORTAL
Thomas Samuel FULFORD
Dale Ian GODFREY
Andrew HAMMET
Simone OSTROUSKA
Con Panousis
Adam Peter ULDRICH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Melbourne
CSL Innovation Pty Ltd
Olivia Newton John Cancer Research Institute
Original Assignee
University of Melbourne
CSL Innovation Pty Ltd
Olivia Newton John Cancer Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2019902308A external-priority patent/AU2019902308A0/en
Application filed by University of Melbourne, CSL Innovation Pty Ltd, Olivia Newton John Cancer Research Institute filed Critical University of Melbourne
Publication of CA3144755A1 publication Critical patent/CA3144755A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
CA3144755A 2019-06-28 2020-06-26 Method of inhibiting or activating gamma delta t cells Pending CA3144755A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
AU2019902308A AU2019902308A0 (en) 2019-06-28 Method of inhibiting or activating gamma delta t cells
AU2019902308 2019-06-28
AU2019904771A AU2019904771A0 (en) 2019-12-17 Method of inhibiting or activating gamma delta t cells
AU2019904773 2019-12-17
AU2019904771 2019-12-17
AU2019904773A AU2019904773A0 (en) 2019-12-17 Method of inhibiting or activating gamma delta t cells
PCT/AU2020/050662 WO2020257871A1 (en) 2019-06-28 2020-06-26 Method of inhibiting or activating gamma delta t cells

Publications (1)

Publication Number Publication Date
CA3144755A1 true CA3144755A1 (en) 2020-12-30

Family

ID=74059614

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3144755A Pending CA3144755A1 (en) 2019-06-28 2020-06-26 Method of inhibiting or activating gamma delta t cells

Country Status (8)

Country Link
US (1) US20220273713A1 (https=)
EP (1) EP3990496A4 (https=)
JP (2) JP2022539753A (https=)
KR (1) KR20220100567A (https=)
CN (1) CN114746445A (https=)
AU (1) AU2020301813A1 (https=)
CA (1) CA3144755A1 (https=)
WO (1) WO2020257871A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022109110A1 (en) * 2020-11-19 2022-05-27 Shattuck Labs, Inc. Methods of identifying gamma delta t cell-modulating agents
US20250179144A1 (en) * 2021-12-09 2025-06-05 The University Of Melbourne Modified Butyrophilin and Butyrophilin Complexes
EP4638472A1 (en) * 2022-12-19 2025-10-29 UMC Utrecht Holding B.V. Btn2a1 binding peptide
WO2025031287A1 (zh) * 2023-08-04 2025-02-13 江苏恒瑞医药股份有限公司 Btn3a结合蛋白及其医药用途
WO2025045192A1 (en) * 2023-08-31 2025-03-06 Biosion Inc. Antibodies binding btn3a1 and uses thereof
WO2025064752A1 (en) * 2023-09-20 2025-03-27 La Jolla Institute For Immunology Human anti-sars-cov-2 spike (s) antibodies
WO2025082418A1 (zh) * 2023-10-18 2025-04-24 苏州沙砾生物科技有限公司 一种鉴定靶标的方法及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0717101D0 (en) * 2007-09-03 2007-10-10 Cambridge Entpr Ltd Tumour marker
JP2016540046A (ja) * 2013-11-29 2016-12-22 シーエスエル、リミテッド ガンの治療方法
EP3827838B1 (en) * 2015-12-16 2023-06-07 The Walter and Eliza Hall Institute of Medical Research Inhibition of cytokine-induced sh2 protein in nk cells
WO2017149394A1 (en) * 2016-02-29 2017-09-08 Ose Immunotherapeutics Non-antagonistic antibodies directed against the alpha chain of the il7 receptor extracellular domain and use thereof in cancer treatment
KR102764182B1 (ko) * 2017-09-21 2025-02-07 임체크 테라퓨틱스 Ｂｔｎ２에 대해 특이성을 갖는 항체 및 이의 용도

Also Published As

Publication number Publication date
AU2020301813A1 (en) 2022-01-27
WO2020257871A1 (en) 2020-12-30
KR20220100567A (ko) 2022-07-15
EP3990496A1 (en) 2022-05-04
US20220273713A1 (en) 2022-09-01
JP2025090566A (ja) 2025-06-17
EP3990496A4 (en) 2023-08-09
JP2022539753A (ja) 2022-09-13
CN114746445A (zh) 2022-07-12

Similar Documents

Publication Publication Date Title
US20220273713A1 (en) Method of inhibiting or activating gamma delta t cells
KR102629403B1 (ko) Vista 항원 결합 분자
US10604576B2 (en) Antibodies and immunocytokines
JP2021184731A (ja) Ｃｄ１２７に対する抗体
JP7022067B2 (ja) Ｆｏｘｐ３由来のペプチドに特異的なｔ細胞受容体様抗体
EP3648786A1 (en) Fusion molecules targeting immune regulatory cells and uses thereof
TW201734046A (zh) 抗體和使用彼之方法
US11919953B2 (en) TIGIT and CD112R blockade
KR20230113752A (ko) Cd39 및 tgf베타를 표적화하는 신규 접합체 분자
WO2023036326A1 (zh) 抗人cd3抗体及其应用
US20220162305A1 (en) Antibodies having specificity for btn2 and uses thereof
US20250333527A1 (en) Antibodies capable of binding to ox40, variants thereof and uses thereof
IL295164A (en) Antibody molecules against lilrb3 and their uses
RU2855103C1 (ru) Молекулы антитела к LILRB3 и их применение
WO2023137161A1 (en) Triple blockade of tigit, cd112r, and pd-l1
WO2023218046A1 (en) Binding agents capable of binding to cd27 in combination therapy

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220912

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250619

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20251020

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260211